ReviewFrontiers in pharmacology2026
Vitamin D in male reproduction: molecular mechanisms and pharmacological perspectives.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D has attracted increasing attention in male reproduction, male fertility, and sperm function, but its pharmacological relevance remains incompletely defined. This review synthesizes current evidence on the molecular mechanisms and clinical implications of vitamin D signaling in the male reproductive system. Available experimental and human data suggest that the vitamin D receptor (VDR) and vitamin D-metabolizing enzymes are present in testicular cells, the epididymis, accessory sex glands, and mature spermatozoa, supporting the possibility of both systemic and local actions. Mechanistically, vitamin D may regulate sperm capacitation and progressive motility through calcium-dependent non-genomic pathways. Ligand-activated VDR signaling may also contribute to antioxidant defense, mitochondrial stability, inflammatory control, steroidogenesis, germ-cell survival, and epigenetic regulation, although several of these pathways still require direct validation in human testicular tissue and spermatozoa. Clinically, low circulating 25-hydroxyvitamin D has been most consistently associated with impaired sperm motility, whereas associations with sperm concentration, total sperm count, reproductive hormones, and sperm DNA fragmentation index are less consistent. Interventional studies suggest that vitamin D supplementation may improve selected semen parameters in deficient men, but current trials do not support broad endocrine or fertility benefits in unselected populations. Importantly, emerging preclinical data indicate that excessive vitamin D exposure may impair spermatogenesis, highlighting a potential biphasic relationship in which both deficiency and excess are unfavorable. Thus, vitamin D should be viewed as a homeostatic modulator rather than a stand-alone treatment for male infertility. Future studies should define optimal therapeutic windows, clarify effects on sperm DNA integrity, and incorporate individual differences in VDR-related genetic and epigenetic regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.